Merck shares may rise as key clinical trial results in oncology and other areas approach.

Bank of America maintains a 'buy' rating on Merck, anticipating a potential share re-rating due to upcoming clinical trial data in oncology and other pipeline areas. Key trials include Phase 3 results for SAC-TMT in lung cancer and data on intismeran, a personalized cancer vaccine developed with Moderna, with presentations expected at the European Society for Medical Oncology meeting. Despite a recent dip, Merck maintains a strong market cap and positive investor interest.